SCHEMBL17635609

SCHEMBL17635609

CCCCCC(C)n1cnc2c(Cl)nc(Cl)nc21

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADA P00813 5/20 0.39
PDE2A O00408 3/20 0.39
CYP3A4 P08684 2/20 0.39
CDK1 P06493 2/20 0.39
PDE4A P27815 1/20 0.39
PDE4B Q07343 1/20 0.39
PDE4C Q08493 1/20 0.39
PDE4D Q08499 1/20 0.39
KDM4E B2RXH2 1/20 0.39
ALDH1A1 P00352 1/20 0.39
CYP1A2 P05177 1/20 0.39
ALOX15 P16050 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
HSD17B10 Q99714 1/20 0.39
TSHR P16473 1/20 0.39
HIF1A Q16665 1/20 0.39
LMNA P02545 1/20 0.39
BLM P54132 1/20 0.39
CCNA2 P20248 5/20 0.38
CDK2 P24941 5/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30331956 0.84 ADORA2A (0.50) CDK1LMNACCNA2CDK2CCNA1
SCHEMBL946328 0.84 ADORA2A (0.50) CDK1LMNACCNA2CDK2CCNA1
SCHEMBL29782935 0.81 ADA (0.38) ADAPDE2ACYP3A4PDE4APDE4B
SCHEMBL24476401 0.80 P2RX7 (0.41) ADAPDE2ACYP3A4CDK1PDE4A
SCHEMBL24476294 0.80 P2RX7 (0.41) ADAPDE2ACYP3A4CDK1PDE4A
SCHEMBL29782919 0.78 LMNA (0.38) CDK1KDM4ELMNACCNA2CDK2
SCHEMBL946796 0.78 CDK1 (0.41) PDE2ACDK1PDE4DLMNACCNA2
SCHEMBL539356 0.78 CDK2 (0.56) CDK1KDM4ECCNA2CDK2CCNA1
SCHEMBL29426182 0.78 CDK2 (0.56) CDK1KDM4ECCNA2CDK2CCNA1
SCHEMBL24476397 0.78 ALDH1A1 (0.37) ADAPDE2ACYP3A4PDE4APDE4B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3000813-A1 PURINE DERIVATIVES FOR USE IN THE TREATMENT OF ALLERGIC, INFLAMMATORY AND INFECTIOUS DISEASES GlaxoSmithKline LLC (US) 2016-03-30 EP disclosed